| Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance I Kareva, DJ Waxman, GL Klement Cancer letters 358 (2), 100-106, 2015 | 262 | 2015 |
| Tumors induce complex DNA damage in distant proliferative tissues in vivo CE Redon, JS Dickey, AJ Nakamura, IG Kareva, D Naf, S Nowsheen, ... Proceedings of the National Academy of Sciences 107 (42), 17992-17997, 2010 | 182 | 2010 |
| The emerging “hallmarks” of metabolic reprogramming and immune evasion: distinct or linked? I Kareva, P Hahnfeldt Cancer research 73 (9), 2737-2742, 2013 | 125 | 2013 |
| Identifying key questions in the ecology and evolution of cancer AM Dujon, A Aktipis, C Alix‐Panabières, SR Amend, AM Boddy, JS Brown, ... Evolutionary applications 14 (4), 877-892, 2021 | 85 | 2021 |
| A combination of immune checkpoint inhibition with metronomic chemotherapy as a way of targeting therapy-resistant cancer cells I Kareva International journal of molecular sciences 18 (10), 2134, 2017 | 75 | 2017 |
| What can ecology teach us about cancer? I Kareva Translational oncology 4 (5), 266-270, 2011 | 75 | 2011 |
| Quantitative systems pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm V Chelliah, G Lazarou, S Bhatnagar, JP Gibbs, M Nijsen, A Ray, B Stoll, ... Clinical Pharmacology & Therapeutics 109 (3), 605-618, 2021 | 68 | 2021 |
| Prisoner's dilemma in cancer metabolism I Kareva PloS one 6 (12), e28576, 2011 | 50 | 2011 |
| Normal wound healing and tumor angiogenesis as a game of competitive inhibition I Kareva, A Abou-Slaybi, O Dodd, O Dashevsky, GL Klement PLOS ONE 11 (12), e0166655, 2016 | 45 | 2016 |
| Metabolism and gut microbiota in cancer immunoediting, CD8/Treg ratios, immune cell homeostasis, and cancer (immuno) therapy: concise review I Kareva Stem Cells 37 (10), 1273-1280, 2019 | 42 | 2019 |
| Cancer immunoediting: a process driven by metabolic competition as a predator–prey–shared resource type model I Kareva, F Berezovskaya Journal of theoretical biology 380, 463-472, 2015 | 40 | 2015 |
| Immune suppression in pregnancy and cancer: parallels and insights I Kareva Translational oncology 13 (7), 100759, 2020 | 37 | 2020 |
| Delicate balances in cancer chemotherapy: Modeling immune recruitment and emergence of systemic drug resistance AP Tran, MA Al-Radhawi, I Kareva, J Wu, DJ Waxman, ED Sontag Frontiers in Immunology 11 (1376), 2020 | 35 | 2020 |
| Replicator Equations and Models of Biological Populations andCommunities GP Karev, IG Kareva Mathematical Modelling of Natural Phenomena 9 (3), 68-95, 2014 | 34 | 2014 |
| Predator-prey in tumor-immune interactions: A wrong model or just an incomplete one? I Kareva, KA Luddy, C O’Farrelly, RA Gatenby, JS Brown Frontiers in Immunology 12, 668221, 2021 | 33 | 2021 |
| How should cancer models be constructed? RA Beckman, I Kareva, FR Adler Cancer Control 27 (1), 1073274820962008, 2020 | 26 | 2020 |
| Cancer Ecology: Niche Construction, Keystone Species, Ecological Succession, and Ergodic Theory I Kareva Biological Theory, 1-6, 2015 | 25 | 2015 |
| Immune evasion through competitive inhibition: the shielding effect of cancer non-stem cells I Kareva Journal of theoretical biology 364, 40-48, 2015 | 23 | 2015 |
| Myeloid cells in tumour–immune interactions I Kareva, F Berezovskaya, C Castillo-Chavez Journal of biological dynamics 4 (4), 315-327, 2010 | 22 | 2010 |
| Biological stoichiometry in tumor micro-environments I Kareva PloS one 8 (1), e51844, 2013 | 21 | 2013 |
Georgy KarevNational Institute of Health, Bethesda MD, USAAdresă de e-mail confirmată pe ncbi.nlm.nih.gov
